Truist Securities raises Encompass Health stock price target to $140 on upbeat outlook

Truist Securities raised its price target on Encompass Health (EHC) to $140 from $135, maintaining a Buy rating, citing robust underlying fundamentals, strong demand trends, and an upbeat management meeting. This optimism is underpinned by EHC's recent Q2 2025 earnings beat, 11.8% revenue growth, and strategic expansion efforts, positioning the company for continued growth. The stock, already up 29.63% year-to-date and near its 52-week high, also benefits from strong financial health and upward revisions from multiple analysts.

Analysis

Encompass Health Corp. (EHC) has received a notable vote of confidence from Truist Securities, which raised its price target to $140.00 from $135.00 while reiterating a Buy rating. This upgrade is predicated on an upbeat management meeting that underscored strong underlying fundamentals, including robust demand trends and significant unmet needs within the healthcare sector. The company's financial performance substantiates this optimism, with a reported 11.8% revenue growth over the last twelve months and a consistent dividend payment history spanning 13 years. Recent results for Q2 2025 further reinforce this positive momentum, with EPS of $1.40 significantly beating the $1.21 consensus and revenue of $1.46 billion surpassing the $1.43 billion forecast. This sentiment is broadly shared, as indicated by nine analysts revising earnings expectations upward. The company's strategic initiatives, including investments in technology and AI, ongoing labor improvements, and physical expansion such as the planned 50-bed hospital in Texas, position it to leverage its strong cash flow for continued growth, market share capture, and shareholder returns via buybacks.

Key Decisions for Investors

• Given the strong consensus from analysts, a significant Q2 earnings beat, and a new price target of $140, investors could view the current momentum as a validation of the company's growth strategy and market position.
• Investors should monitor the execution of expansion projects, like the new Texas hospital, and the sustainability of revenue growth as key indicators of whether the company can achieve its heightened valuation targets.
• While fundamentals are strong, prospective investors should note the stock is trading near its 52-week high following a 29.63% year-to-date appreciation, warranting careful consideration of entry points.